Daily Alpha · Substack
The usable newsletter excerpts offered one optical earnings checkpoint, one GLP-1 market-size frame and one explicit silver-miner short allocation.
Themes on this desk
Optical test demand
VIAV's fifth straight beat came with a guide roughly 50% above consensus.
GLP-1 economics
Chamath framed two 2025 drugs at $71 billion of revenue with under 2% patient penetration.
Silver-miner positioning
Rooster disclosed a 20% allocation to a leveraged SILJ short without a public thesis.
VIAV's fifth straight beat came with a much stronger guide
Asymmetrical Bets says VIAV beat its own guidance for a fifth straight quarter and guided Q1 about 50% above consensus.
The preview strengthens the optical-test demand signal alongside AAOI's capacity commentary.
Watch Q1 delivery, margins, 1.6T test demand and CPO yields.
Source →Chamath framed GLP-1 as a $71 billion market with low penetration
Chamath's public excerpt says two drugs earned $71 billion in 2025 while reaching under 2% of qualifying patients.
The figures frame a large adoption runway, though the excerpt does not identify the drugs or provide the full economics.
Watch Patient penetration, pricing, capacity and competitive launches.
Source →Rooster disclosed a 20% SILJ leveraged-short allocation
The public newsletter text names a leveraged SILJ short and states a 20% allocation in a US ETF.
The allocation is explicit, but the excerpt provides no thesis, target or risk control.
Watch SILJ price, any stop, covering disclosure or allocation change.
Source →